MedPath

Ayurvedic management of Allergic Rhinitis with oral medicine and nasal drops.

Phase 2
Completed
Conditions
Allergic rhinitis, unspecified,
Registration Number
CTRI/2016/02/006661
Lead Sponsor
Institute for Post Graduate Teaching and Research in Ayurveda
Brief Summary

it is a RCT with MOST (Multiphase Optimization STrayegy) approach To evaluate the role of Shirisha Ashwagandhadi Avaleha and Anu Taila Nasya in the management of Allergic rhinitis. In one group Ayurvedic medicine which includes Shirish Ashwagandhadi Avaleha 10 gms twice a day and Anu Taila Pratimarsha Nasya (Imstilation of 2 drops of Anu Taila in both nostrils daily will be given to 50 patients for 60 days). other group is Placebo group in which Placebo capsule will be given once daily to 50 patients for 60 days. It is hypothesised in this study that Ayurvedic Medicine will be effective in treatment of Allergic rhinitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
100
Inclusion Criteria

Patients fulfilling the diagnostic criteria based on sighns and symptoms of Vataja Pratishyaya (Allergic Rhinitis) according to Ayurvedic classics and modern science.

Exclusion Criteria
  • Cases which require surgical intervention like nasal polyps would be excluded.
  • Patients suffering from any chronic debilitating disease like T.B., D.M., Asthma and other respiratory or nasal problems.
  • Pregnant ladies and lactating mothers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sign and symptoms of Allergic Rhinitis will subside.60 days
Secondary Outcome Measures
NameTimeMethod
quality of life and functions of Pranavaha Srotas will improvetill present study

Trial Locations

Locations (1)

Department of Shalakya Tantra

🇮🇳

Jamnagar, GUJARAT, India

Department of Shalakya Tantra
🇮🇳Jamnagar, GUJARAT, India
Parth Prakashbhai Dave
Principal investigator
9638948973
drppdave88@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.